Skip to main content
. Author manuscript; available in PMC: 2023 Jan 19.
Published in final edited form as: ACS Appl Mater Interfaces. 2022 Jan 7;14(2):2488–2500. doi: 10.1021/acsami.1c17415

Figure 3.

Figure 3.

Long-term HIV-1 inhibition of RPV and CAB loaded NPs in CD169+ MDMs. CD169+ MDMs were pre-treated with GM3 PLA NPs, DOPS PLA NPs, GM3 PLGA NPs, or free ARVs at a fixed initial 1 μM RPV concentration for 3 h. Infections were carried with a pseudotyped HIV-1 virus on day 1, 7, 14, 21, 28, and 35 post drug addition. Infection data was collected 3 days post infection. The percentage of infection is normalized to untreated cells. Each data point represents CD169+ MDMs from a different donor, and CD169+ MDMs derived from at least 4 donors were used. Error bars represent SEMs. Results were analyzed by one-way ANOVA with Tukey multiple comparisons test, *P ≤ 0.05 **P ≤ 0.01 ***P ≤ 0.001 ****P ≤ 0.0001.